Stocks News

LAST PRICE
770.0000
TODAY'S CHANGE (%)
Trending Down-1.1200 (-0.1452%)

Bid / Lots
767.1800/ 1
Ask / Lots
775.0000/ 1
Open / Previous Close
772.8900 / 771.1200
Day Range
Low 767.1000
High 774.8700
52 Week Range
Low 419.8000
High 800.7800
Volume
1,670,317
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ Dow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today. -- Barrons.com, from 6:43AM ET on Friday May 17, 2024 by Dow Jones
  6:43AM ET on Friday May 17, 2024 by Dow Jones
  Companies Mentioned: LLY, NVO, RHHBY, WMT, AMZN, BRK.A, BRK.B
  
  Everyone likes a big round number, and 40,000 sure does sound great. That's the mark the Dow Jones Industrial Average briefly exceeded on Thursday, before losing its gains to close at its second-highest level ever.
May 16, 2024
- DJ Roche's New Weight-Loss Data Shows Lilly Isn't Unbeatable in Obesity -- Barrons.com, from 10:08AM ET on Thursday May 16, 2024 by Dow Jones
  10:08AM ET on Thursday May 16, 2024 by Dow Jones
  Companies Mentioned: LLY, NVO, RHHBY, AMGN, VKTX
  
  By Josh Nathan-Kazis
  
  Roche unveiled impressive early-stage results in a small trial of a weight-loss drug called CT-388 that could make the company a serious player in the obesity-drug market in the coming years.
- Eli Lilly's Once-Weekly Insulin Efsitora Alfa Meets Primary Endpoint in Late-Stage Studies, from 7:55AM ET on Thursday May 16, 2024 by MT Newswires
  7:55AM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: LLY
  07:55 AM EDT, 05/16/2024 (MT Newswires) -- Eli Lilly (LLY) said Thursday that its once-weekly insulin efsitora alfa for type 2 diabetes met the primary endpoint in two late-stage clinical trials. In both tests, efsitora showed non-inferior reduction...
- DJ Eli Lilly Says Once-Weekly Insulin Meets Key Goal in Two Studies, from 7:19AM ET on Thursday May 16, 2024 by Dow Jones
  7:19AM ET on Thursday May 16, 2024 by Dow Jones
  Companies Mentioned: LLY
  
  By Colin Kellaher
  
  Eli Lilly on Thursday said a pair of late-stage studies of its proposed once-weekly insulin efsitora alfa met their primary endpoints.
  
  The Indianapolis drugmaker said efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally in the Phase 3 studies in adults with type 2 diabetes using insulin for the first time and those who require multiple daily injections.
- With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin, from 6:45AM ET on Thursday May 16, 2024 by PR Newswire
  6:45AM ET on Thursday May 16, 2024 by PR Newswire
  Companies Mentioned: LLY
  Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes
  Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists

Yesterday
- Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target, from 7:56AM ET on Friday May 17, 2024 by MT Newswires
  7:56AM ET on Friday May 17, 2024 by MT Newswires
  Companies Mentioned: ABBV
- AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week(R), from 7:30AM ET on Friday May 17, 2024 by PR Newswire
  7:30AM ET on Friday May 17, 2024 by PR Newswire
  Companies Mentioned: ABBV
May 16, 2024
- AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial, from 1:12PM ET on Thursday May 16, 2024 by MT Newswires
  1:12PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: AZN
May 15, 2024
- Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline, from 6:45AM ET on Wednesday May 15, 2024 by Business Wire
  6:45AM ET on Wednesday May 15, 2024 by Business Wire
  Companies Mentioned: MRK
May 13, 2024
- Update: AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study, from 1:35PM ET on Monday May 13, 2024 by MT Newswires
  1:35PM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: AZN
- AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study, from 12:43PM ET on Monday May 13, 2024 by MT Newswires
  12:43PM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: AZN
- --AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study, from 12:38PM ET on Monday May 13, 2024 by MT Newswires
  12:38PM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: AZN
- AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders, from 9:34AM ET on Monday May 13, 2024 by MT Newswires
  9:34AM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: ABBV
- AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders, from 8:39AM ET on Monday May 13, 2024 by PR Newswire
  8:39AM ET on Monday May 13, 2024 by PR Newswire
  Companies Mentioned: ABBV
- Merck Halts Drug Combination Arm of Study Testing Potential Melanoma Treatment, from 7:58AM ET on Monday May 13, 2024 by MT Newswires
  7:58AM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: MRK

Eli Lilly and Co
NYSE:LLYUnited States

Search Criteria

Yesterday

DJ Dow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today. -- Barrons.com, from 6:43AM ET on Friday May 17, 2024 by Dow Jones

May 16, 2024

DJ Roche's New Weight-Loss Data Shows Lilly Isn't Unbeatable in Obesity -- Barrons.com, from 10:08AM ET on Thursday May 16, 2024 by Dow Jones

Eli Lilly's Once-Weekly Insulin Efsitora Alfa Meets Primary Endpoint in Late-Stage Studies, from 7:55AM ET on Thursday May 16, 2024 by MT Newswires

DJ Eli Lilly Says Once-Weekly Insulin Meets Key Goal in Two Studies, from 7:19AM ET on Thursday May 16, 2024 by Dow Jones

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin, from 6:45AM ET on Thursday May 16, 2024 by PR Newswire

Peers Headlines

Yesterday

Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target, from 7:56AM ET on Friday May 17, 2024 by MT Newswires

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week(R), from 7:30AM ET on Friday May 17, 2024 by PR Newswire

May 16, 2024

AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial, from 1:12PM ET on Thursday May 16, 2024 by MT Newswires

May 15, 2024

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline, from 6:45AM ET on Wednesday May 15, 2024 by Business Wire

May 13, 2024

Update: AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study, from 1:35PM ET on Monday May 13, 2024 by MT Newswires

AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study, from 12:43PM ET on Monday May 13, 2024 by MT Newswires

--AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study, from 12:38PM ET on Monday May 13, 2024 by MT Newswires

AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders, from 9:34AM ET on Monday May 13, 2024 by MT Newswires

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders, from 8:39AM ET on Monday May 13, 2024 by PR Newswire

Merck Halts Drug Combination Arm of Study Testing Potential Melanoma Treatment, from 7:58AM ET on Monday May 13, 2024 by MT Newswires